NCT03879603View on ClinicalTrials.gov

VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 2, 2019

Primary Completion Date

February 26, 2020

Study Completion Date

February 26, 2020

Conditions
Venezuelan Equine EncephalitisWestern Equine EncephalitisEastern Equine EncephalitisAlphavirus Infections
Interventions
BIOLOGICAL

VRC-WEVVLP073-00-VP

VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)

OTHER

VRC-GENMIX083-AL-VP

VRC-GENMIX083-AL-VP is an adjuvant

Trial Locations (1)

30030

The Hope Clinic of the Emory Vaccine Center, Decatur

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03879603 - VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults | Biotech Hunter | Biotech Hunter